ADAPTIVE BIOTECHNOLOGIES (ADPT)
US00650F1093 - Common Stock
Overall ADPT gets a fundamental rating of 2 out of 10. We evaluated ADPT against 55 industry peers in the Life Sciences Tools & Services industry. Both the profitability and financial health of ADPT have multiple concerns. ADPT is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year ADPT has reported negative net income.
ADPT had a negative operating cash flow in the past year.
ADPT had negative earnings in each of the past 5 years.
ADPT had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
With a Return On Assets value of -36.50%, ADPT is not doing good in the industry: 80.00% of the companies in the same industry are doing better.
ADPT has a Return On Equity of -88.36%. This is amonst the worse of the industry: ADPT underperforms 81.82% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -36.5% | ||
| ROE | -88.36% | ||
| ROIC | N/A |
ROA(3y)-26.63%
ROA(5y)-20.12%
ROE(3y)-50.16%
ROE(5y)-36.47%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 54.77%, ADPT is in the better half of the industry, outperforming 69.09% of the companies in the same industry.
ADPT's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for ADPT so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 54.77% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-10.32%
GM growth 5Y-2.96%
2. Health
2.1 Basic Checks
ADPT does not have a ROIC to compare to the WACC, probably because it is not profitable.
ADPT has more shares outstanding than it did 1 year ago.
The number of shares outstanding for ADPT has been increased compared to 5 years ago.
ADPT has a worse debt/assets ratio than last year.
2.2 Solvency
ADPT has an Altman-Z score of -1.81. This is a bad value and indicates that ADPT is not financially healthy and even has some risk of bankruptcy.
ADPT has a worse Altman-Z score (-1.81) than 80.00% of its industry peers.
A Debt/Equity ratio of 0.55 indicates that ADPT is somewhat dependend on debt financing.
ADPT has a Debt to Equity ratio of 0.55. This is in the lower half of the industry: ADPT underperforms 63.64% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.55 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -1.81 |
ROIC/WACCN/A
WACC10.57%
2.3 Liquidity
A Current Ratio of 3.99 indicates that ADPT has no problem at all paying its short term obligations.
The Current ratio of ADPT (3.99) is better than 67.27% of its industry peers.
A Quick Ratio of 3.84 indicates that ADPT has no problem at all paying its short term obligations.
ADPT has a Quick ratio of 3.84. This is in the better half of the industry: ADPT outperforms 69.09% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.99 | ||
| Quick Ratio | 3.84 |
3. Growth
3.1 Past
ADPT shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 3.01%.
The Revenue for ADPT has decreased by -10.99% in the past year. This is quite bad
The Revenue has been growing by 25.04% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)3.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%6.06%
Revenue 1Y (TTM)-10.99%
Revenue growth 3Y20.06%
Revenue growth 5Y25.04%
Sales Q2Q%-11.72%
3.2 Future
ADPT is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.69% yearly.
Based on estimates for the next years, ADPT will show a quite strong growth in Revenue. The Revenue will grow by 14.89% on average per year.
EPS Next Y10.1%
EPS Next 2Y11.88%
EPS Next 3Y12.69%
EPS Next 5YN/A
Revenue Next Year-0.4%
Revenue Next 2Y9.54%
Revenue Next 3Y14.89%
Revenue Next 5YN/A
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for ADPT. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ADPT. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
ADPT's earnings are expected to grow with 12.69% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y11.88%
EPS Next 3Y12.69%
5. Dividend
5.1 Amount
No dividends for ADPT!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ADAPTIVE BIOTECHNOLOGIES
NASDAQ:ADPT (11/4/2024, 8:00:00 PM)
After market: 5.26 0 (0%)5.26
-0.05 (-0.94%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap775.69M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -36.5% | ||
| ROE | -88.36% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 54.77% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.29
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.55 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 3.99 | ||
| Quick Ratio | 3.84 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)3.01%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y10.1%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-10.99%
Revenue growth 3Y20.06%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y